By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Surrozen Inc. has announced that Boehringer Ingelheim Pharma GmbH & Co. KG will further develop SZN-413 to advance the compound and prepare it for clinical testing. Boehringer decided to move forward ...

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...